Purpose The one-dose daily regime of rivaroxaban could cause a pronounced variability in
concentration and effect of which a deeper knowledge is warranted. This study aimed to …

Background: Reduced-dose rivaroxaban (10 mg) was used in the J-ROCKET AF trial,
demonstrating safety in the Asian population. It remains unclear whether treatment with …

Background Routine laboratory monitoring of rivaroxaban and dose adjustment relating to
exposure is currently not recommended. However, in certain clinical situations, assessment …

Background Rivaroxaban is an oral anticoagulant that effectively prevents thromboembolic
complications using fixed doses without requiring laboratory monitoring. In this study, we …

Background: It is unknown whether diltiazem, a moderate cytochrome P450 enzyme
(CYP3A4) and P-glycoprotein (P-gp) inhibitor, increases the incidence of bleeding events in …

Purpose: To evaluate the effectiveness and associated risks of rivaroxaban against warfarin
in Chinese elderly diabetic patients with non-valvular atrial fibrillation. Methods: Data …

Rivaroxaban, a direct factor Xa inhibitor, is widely used for stroke prevention in patients with
non-valvular atrial fibrillation (NVAF). The aim of this study was to conduct a population …

Prothrombin time (PT) has been widely used for measuring anticoagulation intensity under
rivaroxaban therapy, but precise information has not been well established yet. Consecutive …

Background Rivaroxaban is a non‐vitamin K oral anticoagulant and has been approved for
prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation …

Aim: To analyze clinical profile and management of patients with nonvalvular atrial
fibrillation treated with rivaroxaban in clinical practice according to age and to ascertain …